Theranostics 2018; 8(3):812-814. doi:10.7150/thno.24183 This issue Cite
Editorial
1. Department of Medical Physics, University of Wisconsin - Madison, Madison, WI 53705
2. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3. Department of Radiology, University of Wisconsin - Madison, Madison, WI 53705
4. Carbone Cancer Center, University of Wisconsin - Madison, Madison, WI 53705
Although 177Lu-DOTA-TATE was recently approved in Europe for the treatment of certain neuroendocrine tumors, continued development and optimization has been ongoing to further improve the therapeutic efficacy of somatostatin receptor 2 targeted peptide receptor radionuclide therapy, as well as reducing the renal toxicity. In this work, the use of an Evans blue analog for “albumin hitchhiking” resulted in significant improvement in both the imaging performance and therapeutic efficacy of radiolabeled octreotate, as well as reducing the toxicity since much less radioactivity was used for therapy. Upon clinical translation, such “albumin hitchhiking” could make significant impact in the near future for cancer patient management.
Keywords: somatostatin receptor 2 (SSTR2), peptide receptor radionuclide therapy (PRRT), octreotate (TATE), positron emission tomography (PET), theranostics, cancer, precision medicine